Clinical trial
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast…
NCT00127933 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00127933 |
|---|---|
| Title | XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer |
| Official title | An Open-label Study of Xeloda Plus Taxotere on Treatment Response in Patients With HER2-neu-negative, and the Addition of Herceptin for HER2-neu-positive Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine [Xeloda], Taxotere, Herceptin (HER2-neu positive patients only) |
| Enrollment | 157 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Aug 9, 2005 |
| Last update posted | Aug 10, 2011 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: